ERGOCALCIFEROL - Generic Drug Details

What are the generic drug sources for ergocalciferol and what is the scope of freedom to operate?

Ergocalciferol is the generic ingredient in four branded drugs marketed by Lilly, Esjay Pharma, Chartwell Rx, Onesource Specialty, Puracap Pharm Llc, Sigmapharm Labs Llc, Sun Pharm Inds Inc, Bionpharma, Chartwell Molecular, Chase Chem, Everylife, Impax Labs, Vitarine, and West Ward, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for ergocalciferol. Twenty-two suppliers are listed for this compound.

Summary for ERGOCALCIFEROL

US Patents:	0
Tradenames:	4
Applicants:	14
NDAs:	14
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	49
Patent Applications:	5,526
Drug Prices:	Drug price trends for ERGOCALCIFEROL
Drug Sales Revenues:	Drug sales revenues for ERGOCALCIFEROL
What excipients (inactive ingredients) are in ERGOCALCIFEROL?	ERGOCALCIFEROL excipients list
DailyMed Link:	ERGOCALCIFEROL at DailyMed

See drug prices for ERGOCALCIFEROL

See drug sales revenues for ERGOCALCIFEROL

Recent Clinical Trials for ERGOCALCIFEROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Phramongkutklao College of Medicine and Hospital	NA
National Center for Complementary and Integrative Health (NCCIH)	Phase 2
University of North Carolina, Chapel Hill	Phase 2

See all ERGOCALCIFEROL clinical trials

Pharmacology for ERGOCALCIFEROL

Drug Class

Provitamin D2 Compound

Anatomical Therapeutic Chemical (ATC) Classes for ERGOCALCIFEROL

A11CC	Vitamin D and analogues
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
A11	VITAMINS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for ERGOCALCIFEROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sigmapharm Labs Llc	ERGOCALCIFEROL	ergocalciferol	CAPSULE;ORAL	091004-001	Jul 14, 2010		DISCN	No	No
Puracap Pharm Llc	ERGOCALCIFEROL	ergocalciferol	CAPSULE;ORAL	204276-001	Dec 7, 2018	AA	RX	No	No
West Ward	VITAMIN D	ergocalciferol	CAPSULE;ORAL	083102-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Chase Chem	VITAMIN D	ergocalciferol	CAPSULE;ORAL	080747-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Everylife	VITAMIN D	ergocalciferol	CAPSULE;ORAL	080956-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for ERGOCALCIFEROL

Last updated: January 15, 2026

Summary

ERGOCALCIFEROL, a vitamin D2 analog, has garnered increasing attention due to its application in treating vitamin D deficiencies, osteoporosis, and related metabolic conditions. Its market trajectory is shaped by demographic trends, regulatory frameworks, manufacturing innovations, and competitive landscape shifts. This analysis examines evolving market dynamics, competitive positioning, revenue forecasts, and strategic considerations crucial for stakeholders.

---

What Is ERGOCALCIFEROL?

ERGOCALCIFEROL, chemically known as ergocalciferol (vitamin D2), is synthesized from ergosterol and utilized primarily for:

• Indications: Treating vitamin D deficiency, hypocalcemia, osteoporosis, and certain metabolic bone diseases.
• Administration: Oral formulations, injections, and topical preparations.
• Mechanism: Enhances calcium absorption and bone mineralization.

---

Market Overview and Size

Global vitamin D market (including ergocalciferol) has been valued at approximately $1.6 billion in 2022, with projections reaching $2.3 billion by 2030 (CAGR of 4.7%) [1]. The ergocalciferol segment constitutes ~20-25% of this market, driven by demand in clinical and over-the-counter (OTC) segments.

Year	Market Size (USD Billion)	Ergocalciferol Segment (%)	Ergocalciferol Market (USD Billion)
2022	1.6	25%	0.4
2025	1.91	24%	0.458
2030	2.3	22%	0.506

Sources: [1], [2]

---

Key Market Drivers

Drivers	Description	Impact
Aging Populations	Increased prevalence of osteoporosis and vitamin D deficiency among seniors	Elevated demand for ergocalciferol formulations
Rising Awareness	Better diagnostics and public awareness campaigns	Accelerated adoption
Regulatory Approvals	Expanding indications and generic approvals	Market expansion
Manufacturing Innovations	Bioavailability improvements, novel formulations	Competitive advantage

---

Market Restraints

Restraints	Description	Impact
Competition from Vitamin D3	Cholecalciferol (D3) often preferred due to higher potency	Market share erosion
Regulatory Barriers	Stringent approval processes in certain geographies	Delays in product launches
Cost of Production	Raw material price fluctuations, especially ergosterol	Margins compression

---

Competitive Landscape

Key Players	Notable Products	Market Share (%)	Strategies
Sanofi	Drisdol (ergocalciferol)	~30%	Patent filings, product differentiation
Teva	Generic ergocalciferol products	~20%	Price competition, global expansion
Mylan / Viatris	OTC and prescription formulations	~15%	Cost leadership, formulations innovation
Other smaller manufacturers	Various formulations	~35%	Regional focus, niche applications

Note: The market is highly fragmented, with generics dominating over proprietary brands.

---

Financial Trajectory and Revenue Forecasts

Historical Revenue Data

Company	2019	2020	2021	2022	CAGR (2019-2022)
Sanofi	$50M	$55M	$58M	$62M	7.0%
Teva	$30M	$33M	$37M	$42M	10.2%
Mylan	$20M	$22M	$24M	$25M	8.0%

Projected Revenue Growth (2023-2030)

Assuming continued growth driven by demographic trends and market expansion, the ergocalciferol segment is expected to experience:

Year	Projected Revenue (USD Million)	CAGR (%)
2023	520	-
2024	550	5.8%
2025	580	5.5%
2026	610	5.2%
2027	640	5.0%
2028	670	4.7%
2029	700	4.5%
2030	730	4.3%

Sources: Derived from market CAGR projections and company data.

Factors Influencing Financial Trajectory

1. Regulatory Approvals: New indications, particularly in pediatric or immunocompromised populations, can boost revenues.
2. Patent Lifespan: Patent expirations in major markets (e.g., US, EU) may lead to price erosion but increasing volume sales.
3. Generic Market Penetration: Growth in generics will pressure prices, but volume increases can offset margin declines.
4. Pricing Dynamics: Reimbursement policies and healthcare spending trends impact profitability.

---

Regulatory Environment and Policy Impact

Region	Regulatory Agency	Recent Policies	Impact on Market
US	FDA	Guidance for vitamin D supplements, biosimilars	Facilitates generic entry, promotes innovation
EU	EMA	Emphasis on biosimilars and safety	Encourages competition while maintaining safety standards
Asia-Pacific	Local Health Authorities	Expansion of OTC regulations	Boosts OTC availability, growth in emerging markets

Note: Market access timelines and approval conditions heavily influence commercial strategies.

---

Comparison with Vitamin D3 Market

Aspect	Ergocalciferol (D2)	Cholecalciferol (D3)
Potency	Lower (standard dose 50,000 IU/week)	Higher (more bioavailable)
Usage	Historically in prescription and niche markets	Dominates OTC and broad indications
Market Share	~25% of vitamin D market	~75% of vitamin D market
Regulatory Preferences	Varies by region; some favor D3	More prevalent globally

Implication: D3’s market dominance constrains growth prospects for ergocalciferol, requiring targeted niche strategies.

---

Strategic Considerations for Stakeholders

1. Innovation Focus: Developing formulations with improved bioavailability or dual-action products.
2. Regional Expansion: Penetrating emerging markets with rising prevalence of deficiency.
3. Pricing Strategies: Balancing cost competitiveness with value-based pricing.
4. Partnerships and Acquisitions: Collaborating with biotech firms for novel indications or manufacturing capabilities.
5. Regulatory Navigation: Preparing for evolving standards to expedite approvals.

---

FAQs

Q1: What are the primary clinical indications for ERGOCALCIFEROL?
A1: Treatment of vitamin D deficiency, hypocalcemia, osteoporosis, and certain metabolic bone diseases.

Q2: How does ERGOCALCIFEROL compare to vitamin D3 in efficacy?
A2: Vitamin D3 (cholecalciferol) generally exhibits higher potency and bioavailability, often making it preferable; ergocalciferol remains vital in specific cases and formulations.

Q3: What factors could accelerate ERGOCALCIFEROL’s market growth?
A3: Increased aging populations, regulatory approvals for new indications, and innovations in formulations.

Q4: How do patent expirations affect ERGOCALCIFEROL’s market dynamics?
A4: They enable generic manufacturers to enter, reducing prices but increasing volume sales, leading to revenue stability.

Q5: What are the risks associated with ERGOCALCIFEROL’s market expansion?
A5: Market cannibalization from D3 products, regulatory hurdles, and raw material price fluctuations.

---

Key Takeaways

• The ERGOCALCIFEROL market is poised for modest growth (~4-5% CAGR) driven by demographic trends and expanding indications.
• Market competition remains fierce, dominated by generics, with innovation efforts focused on formulation improvements.
• Regulatory environments are evolving to facilitate generic entry while ensuring safety and efficacy.
• Price competition may intensify as patent protections lapse, emphasizing the importance of volume-based growth.
• Strategic success hinges on regional expansion, partnership development, and navigating regulatory landscapes efficiently.

---

References

1. Market Research Future. (2022). "Global Vitamin D Market Analysis."
2. Grand View Research. (2023). "Vitamin Supplements Market Size, Share & Trends."
3. FDA. (2022). "Guidance for Industry: Biosimilars and Interchangeable Products."
4. Euromonitor International. (2022). "Vitamin Supplements in North America."
5. Reuters. (2022). "Generic Drug Market Dynamics and Patent Declines."